Thursday, March 7, 2013
Although 2-hydroxyglutarate is a known marker for various cancers, including leukemia,1,2
the metabolite's role in the disease remained unclear. Now, U.S. researchers
have shown that the compound itself can drive leukemic transformation and that
blocking its overproduction with a small molecule from Agios Pharmaceuticals Inc. reversed the effect.3
New research directions
The data reported in the paper open up
new therapeutic avenues for IDH1-mutant cancers, such as targeting the
transformation phenomenon, direct inhibition of 2-HG itself or going after the
metabolite's downstream targets.
Lou, K.-J. SciBX 6(9); doi:10.1038/scibx.2013.205 Published online March
1. Gross, S. et al. J.
Exp. Med. 207, 339-344 (2010)
2. Ward, P.S. et al.
Cancer Cell 17, 225-234 (2010)
3. Losman, J.-A. et al.
Science; published online Feb. 7, 2013; doi:10.1126/science.1231677 Contact:
William Kaelin Jr., Dana-Farber Cancer Institute, Boston, Mass. e-mail: email@example.com
4. Dang, L. et al.
Nature 462, 739-744 (2009)
5. Lou, K.-J. SciBX
6. Ward, M. BioCentury
18(18), A7; April 19, 2010
AND INSTITUTIONS MENTIONED
Agios Pharmaceuticals Inc., Cambridge, Mass.
Celgene Corp. (NASDAQ:CELG), Summit, N.J.
Dana-Farber Cancer Institute, Boston, Mass.
Howard Hughes Medical Institute, Chevy Chase, Md.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.